BEIJING (Reuters) – The Peruvian and Moroccan governments approved Phase 3 clinical trials for a COVID-19 vaccine developed through the National Biotec Group of China (CNBG), the company said Thursday on the Chinese social media platform WeChat.
Phase 3 trials, involving several thousand participants, allow researchers to gather knowledge about the effectiveness of prospective vaccines for final regulatory approvals.
THE experimental vaccine of CNBG, a unit of the public pharmaceutical company China National Pharmaceutical Group (Sinopharm), has entered a phase 3 trial in the United Arab Emirates that has already recruited 15,000 volunteers. bit.ly/2YhL5pJ
It also granted permission to be tested in Bahrain as a component of a Phase 3 exam intended to involve approximately 6,000 component participants.
Reporting through Roxanne Liu and Tony Munroe in Beijing; Editing via Shri Navaratnam and Stephen Coates
All quotes were delayed for at least 15 minutes. See here for a complete list of transactions and delays.
© 2020 Reuters. All rights are reserved.